Literature DB >> 3399084

Basal ganglia calcifications in a case of biotinidase deficiency.

P E Schulz1, S P Weiner, J W Belmont, M A Fishman.   

Abstract

Biotinidase deficiency leads to a biotin-deficient state, with cardinal symptoms of ataxia, alopecia, and skin rash presenting in infancy. Previous reports of head CTs in patients with biotinidase deficiency did not note basal ganglia calcifications. We report the first case of biotinidase deficiency with basal ganglia calcifications. There were no symptoms referable to basal ganglia dysfunction.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3399084     DOI: 10.1212/wnl.38.8.1326

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  5 in total

1.  Cerebral metabolic change after treatment in biotinidase deficiency.

Authors:  I T Lott; S Lottenberg; W L Nyhan; M J Buchsbaum
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

2.  Normalisation of severe cranial CT scan abnormalities after biotin in a case of biotinidase deficiency.

Authors:  H D Bakker; M Westra; W C Overweg-Plandsoen; G van Waveren; J H Sillevis Smitt; N G Abeling; R J Wanders; R B Schutgens; A H van Gennip
Journal:  Eur J Pediatr       Date:  1994-11       Impact factor: 3.183

3.  Impaired biotinidase activity disrupts holocarboxylase synthetase expression in late onset multiple carboxylase deficiency.

Authors:  Anylu Pérez-Monjaras; Rafael Cervantes-Roldán; Iván Meneses-Morales; Roy A Gravel; Sandra Reyes-Carmona; Sergio Solórzano-Vargas; Alfonso González-Noriega; Alfonso León-Del-Río
Journal:  J Biol Chem       Date:  2008-10-09       Impact factor: 5.157

4.  Biotinidase deficiency: a reversible metabolic encephalopathy. Neuroimaging and MR spectroscopic findings in a series of four patients.

Authors:  Shrinivas Desai; Karthik Ganesan; Anaita Hegde
Journal:  Pediatr Radiol       Date:  2008-06-11

5.  Biotinidase Deficiency: New Directions and Practical Concerns.

Authors:  Barry Wolf
Journal:  Curr Treat Options Neurol       Date:  2003-07       Impact factor: 3.972

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.